FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:39-51 July 5, 2007 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Overexpression of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu or ErbB-2), a 185-kD receptor first described more than two decades ago,¹ occurs in 20 to 30% of invasive breast carcinomas. In general, patients with breast-cancer cells that overexpress this receptor or that have a high copy number of its gene have decreased overall survival and may have differential responses to a variety of chemotherapeutic and hormonal agents.^2,3,4,5,6 Thus, strategies to target HER2 appear to be important in treating breast cancer. One such medication is trastuzumab (Herceptin, Genentech), a humanized monoclonal antibody. Trastuzumab binds to . . . [Full Text of this Article]

Background

Human Epidermal Growth Factor Receptors and Their Functions

HER2 Signaling and Overexpression

Mechanism of Action of Trastuzumab

Results of Clinical Trials

Toxicity

Clinical Significance of HER2 Testing

Studies of Trastuzumab as Adjuvant Therapy

Clinical Use of Trastuzumab

Metastatic Breast Cancer

Adjuvant Therapy for Early-Stage Breast Cancer

Future Directions

Conclusions

Source Information

From the Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York.

Address reprint requests to Dr. Hudis at the Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., P.O. Box 206, New York, NY 10021, or at hudisc@mskcc.org.

Related Letters:

Trastuzumab — Mechanism of Action and Use
Karamouzis M. V., Konstantinopoulos P. A., Papavassiliou A. G., Mir O., Berveiller P., Pons G., Hudis C. A.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:1664-1666, Oct 18, 2007. Correspondence

This article has been cited by other articles:

• Huang, X., Gao, L., Wang, S., Lee, C.-K., Ordentlich, P., Liu, B. (2009). HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression. Cancer Res. 69: 8403-8411 [Abstract] [Full Text]  
• Reim, F., Dombrowski, Y., Ritter, C., Buttmann, M., Hausler, S., Ossadnik, M., Krockenberger, M., Beier, D., Beier, C. P., Dietl, J., Becker, J. C., Honig, A., Wischhusen, J. (2009). Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells. Cancer Res. 69: 8058-8066 [Abstract] [Full Text]  
• McArthur, H. L., Hudis, C. A. (2009). Trastuzumab: A Picky Partner?. Clin. Cancer Res. 15: 6311-6313 [Abstract] [Full Text]  
• Francia, G., Man, S., Lee, C.-J., Lee, C. R., Xu, P., Mossoba, M. E., Emmenegger, U., Medin, J. A., Kerbel, R. S. (2009). Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2-Positive Human Breast Cancer Xenografts. Clin. Cancer Res. 15: 6358-6366 [Abstract] [Full Text]  
• VAN ROOIJ, F. G., DORRESTEIJN, L. D.A., VAN BOKHOVEN, M. M.J.A., VERSTAPPEN, C. C.P. (2009). A Throbbing Pain in the Head: Trastuzumab-induced Migraine. Anticancer Res 29: 4223-4225 [Abstract] [Full Text]  
• Peethambaram, P. P., Melisko, M. E., Rinn, K. J., Alberts, S. R., Provost, N. M., Jones, L. A., Sims, R. B., Lin, L. R. C., Frohlich, M. W., Park, J. W. (2009). A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu. Clin. Cancer Res. 15: 5937-5944 [Abstract] [Full Text]  
• McLarty, K., Cornelissen, B., Cai, Z., Scollard, D. A., Costantini, D. L., Done, S. J., Reilly, R. M. (2009). Micro-SPECT/CT with 111In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts. JNM 50: 1340-1348 [Abstract] [Full Text]  
• Leow, C. C., Chesebrough, J., Coffman, K. T., Fazenbaker, C. A., Gooya, J., Weng, D., Coats, S., Jackson, D., Jallal, B., Chang, Y. (2009). Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib. Molecular Cancer Therapeutics 8: 2131-2141 [Abstract] [Full Text]  
• Dijkers, E. C.F., Kosterink, J. G.W., Rademaker, A. P., Perk, L. R., van Dongen, G. A.M.S., Bart, J., de Jong, J. R., de Vries, E. G.E., Lub-de Hooge, M. N. (2009). Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging. JNM 50: 974-981 [Abstract] [Full Text]  
• Dokmanovic, M., Hirsch, D. S., Shen, Y., Wu, W. J. (2009). Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Molecular Cancer Therapeutics 8: 1557-1569 [Abstract] [Full Text]  
• Woodfield, G. W., Hitchler, M. J., Chen, Y., Domann, F. E., Weigel, R. J. (2009). Interaction of TFAP2C with the Estrogen Receptor-{alpha} Promoter Is Controlled by Chromatin Structure. Clin. Cancer Res. 15: 3672-3679 [Abstract] [Full Text]  
• Abella, J. V., Park, M. (2009). Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am. J. Physiol. Endocrinol. Metab. 296: E973-E984 [Abstract] [Full Text]  
• Hu, X., Stern, H. M., Ge, L., O'Brien, C., Haydu, L., Honchell, C. D., Haverty, P. M., Peters, B. A., Wu, T. D., Amler, L. C., Chant, J., Stokoe, D., Lackner, M. R., Cavet, G. (2009). Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes. Mol Cancer Res 7: 511-522 [Abstract] [Full Text]  
• Barros Costa, R. L. (2009). Review Article: Targeted Therapy: Comprehensive Review. AM J HOSP PALLIAT CARE 26: 137-146 [Abstract]  
• Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N. (2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist 14: 320-368 [Abstract] [Full Text]  
• Magnifico, A., Albano, L., Campaner, S., Delia, D., Castiglioni, F., Gasparini, P., Sozzi, G., Fontanella, E., Menard, S., Tagliabue, E. (2009). Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to Trastuzumab. Clin. Cancer Res. 15: 2010-2021 [Abstract] [Full Text]  
• Iverson, A. A., Gillett, C., Cane, P., Santini, C. D., Vess, T. M., Kam-Morgan, L., Wang, A., Eisenberg, M., Rowland, C. M., Hessling, J. J., Broder, S. E., Sninsky, J. J., Tutt, A., Anderson, S., Chang, S.-Y. P. (2009). A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. J. Mol. Diagn. 11: 117-130 [Abstract] [Full Text]  
• Ma, W. W., Adjei, A. A. (2009). Novel Agents on the Horizon for Cancer Therapy. CA Cancer J Clin 59: 111-137 [Abstract] [Full Text]  
• Terada, K., Okochi-Takada, E., Akashi-Tanaka, S., Miyamoto, K., Taniyama, K., Tsuda, H., Asada, K., Kaminishi, M., Ushijima, T. (2009). Association between frequent CpG island methylation and HER2 amplification in human breast cancers. Carcinogenesis 30: 466-471 [Abstract] [Full Text]  
• Stewart, D. J., Kurzrock, R. (2009). Cancer: The Road to Amiens. JCO 27: 328-333 [Full Text]  
• Morris, P. G., McArthur, H. L., Dang, C. T., Hudis, C. A. (2009). Selection of Appropriate Patients for Anthracycline Therapy. Am Soc Clin Oncol Ed Book 2009: 11-18 [Abstract] [Full Text]  
• Olopade, O. I., Grushko, T. A., Nanda, R., Huo, D. (2008). Advances in Breast Cancer: Pathways to Personalized Medicine. Clin. Cancer Res. 14: 7988-7999 [Abstract] [Full Text]  
• Beum, P. V., Mack, D. A., Pawluczkowycz, A. W., Lindorfer, M. A., Taylor, R. P. (2008). Binding of Rituximab, Trastuzumab, Cetuximab, or mAb T101 to Cancer Cells Promotes Trogocytosis Mediated by THP-1 Cells and Monocytes. J. Immunol. 181: 8120-8132 [Abstract] [Full Text]  
• Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V.J., Lutz, R. J., Wong, W. L. T., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., Sliwkowski, M. X. (2008). Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Res. 68: 9280-9290 [Abstract] [Full Text]  
• Stagg, J., Sharkey, J., Pommey, S., Young, R., Takeda, K., Yagita, H., Johnstone, R. W., Smyth, M. J. (2008). Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc. Natl. Acad. Sci. USA 105: 16254-16259 [Abstract] [Full Text]  
• Rosenberg, C. L. (2008). Polysomy 17 and HER-2 Amplification: True, True, and Unrelated. JCO 26: 4856-4858 [Full Text]  
• Oda, K., Okada, J., Timmerman, L., Rodriguez-Viciana, P., Stokoe, D., Shoji, K., Taketani, Y., Kuramoto, H., Knight, Z. A., Shokat, K. M., McCormick, F. (2008). PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation. Cancer Res. 68: 8127-8136 [Abstract] [Full Text]  
• Horlings, H. M., van Laar, R. K., Kerst, J.-M., Helgason, H. H., Wesseling, J., van der Hoeven, J. J.M., Warmoes, M. O., Floore, A., Witteveen, A., Lahti-Domenici, J., Glas, A. M., Van't Veer, L. J., de Jong, D. (2008). Gene Expression Profiling to Identify the Histogenetic Origin of Metastatic Adenocarcinomas of Unknown Primary. JCO 26: 4435-4441 [Abstract] [Full Text]  
• King, J., Waxman, J., Stauss, H. (2008). Advances in tumour immunotherapy. QJM 101: 675-683 [Abstract] [Full Text]  
• Frohling, S., Dohner, H. (2008). Chromosomal Abnormalities in Cancer. NEJM 359: 722-734 [Full Text]  
• Lee, C. W., Raskett, C. M., Prudovsky, I., Altieri, D. C. (2008). Molecular Dependence of Estrogen Receptor-Negative Breast Cancer on a Notch-Survivin Signaling Axis. Cancer Res. 68: 5273-5281 [Abstract] [Full Text]  
• Chen, M. H., Kerkela, R., Force, T. (2008). Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics. Circulation 118: 84-95 [Full Text]  
• Seruga, B., Tannock, I. F. (2008). Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500?. JCO 26: 2940-2942 [Full Text]  
• McGowan, P. M., McKiernan, E., Bolster, F., Ryan, B. M., Hill, A. D. K., McDermott, E. W., Evoy, D., O'Higgins, N., Crown, J., Duffy, M. J. (2008). ADAM-17 predicts adverse outcome in patients with breast cancer. Ann Oncol 19: 1075-1081 [Abstract] [Full Text]  
• Northey, J. J., Chmielecki, J., Ngan, E., Russo, C., Annis, M. G., Muller, W. J., Siegel, P. M. (2008). Signaling through ShcA Is Required for Transforming Growth Factor {beta}- and Neu/ErbB-2-Induced Breast Cancer Cell Motility and Invasion. Mol. Cell. Biol. 28: 3162-3176 [Abstract] [Full Text]  
• Ludovini, V., Gori, S., Colozza, M., Pistola, L., Rulli, E., Floriani, I., Pacifico, E., Tofanetti, F. R., Sidoni, A., Basurto, C., Rulli, A., Crino, L. (2008). Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 19: 883-890 [Abstract] [Full Text]  
• Karamouzis, M. V., Konstantinopoulos, P. A., Papavassiliou, A. G. (2008). ErbB/HER receptor family in breast cancer--the more we search the more we learn. Ann Oncol 19: 1020-1021 [Full Text]  
• Tatebe, H., Shimizu, M., Shirakami, Y., Tsurumi, H., Moriwaki, H. (2008). Synergistic Growth Inhibition by 9-cis-Retinoic Acid Plus Trastuzumab in Human Hepatocellular Carcinoma Cells. Clin. Cancer Res. 14: 2806-2812 [Abstract] [Full Text]  
• Hynes, N. E (2008). ErbB Receptors in Cancer: HER2/ErbB2 as a Therapeutic Target. aacredbook 2008: 123-130 [Abstract] [Full Text]  
• Oldham, R. K., Dillman, R. O. (2008). Monoclonal Antibodies in Cancer Therapy: 25 Years of Progress. JCO 26: 1774-1777 [Full Text]  
• Anesi, G. L. (2008). Genetically Guided Choices for Chemotherapy. JAMA 299: 1543-1544 [Full Text]  
• Gonzalez-Angulo, A. M., Hortobagyi, G. N. (2008). Optimal Schedule of Paclitaxel: Weekly Is Better. JCO 26: 1585-1587 [Full Text]  
• Baker, J. H.E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J. T., Minchinton, A. I. (2008). Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts. Clin. Cancer Res. 14: 2171-2179 [Abstract] [Full Text]  
• Pusztai, L. (2008). Current Status of Prognostic Profiling in Breast Cancer. The Oncologist 13: 350-360 [Abstract] [Full Text]  
• Pant, S., Landon, M. B., Blumenfeld, M., Farrar, W., Shapiro, C. L. (2008). Treatment of Breast Cancer With Trastuzumab During Pregnancy. JCO 26: 1567-1569 [Full Text]  
• Mayer, E. L., Burstein, H. J. (2008). Weighing a Dose-Dense Option for Adjuvant Chemotherapy and Trastuzumab in Early-Stage Breast Cancer. JCO 26: 1198-1200 [Full Text]  
• Shattuck, D. L., Miller, J. K., Carraway, K. L. III, Sweeney, C. (2008). Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells. Cancer Res. 68: 1471-1477 [Abstract] [Full Text]  
• Cottu, P. H., Asselah, J., Lae, M., Pierga, J.-Y., Dieras, V., Mignot, L., Sigal-Zafrani, B., Vincent-Salomon, A. (2008). Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19: 595-597 [Full Text]  
• Finetti, P., Cervera, N., Charafe-Jauffret, E., Chabannon, C., Charpin, C., Chaffanet, M., Jacquemier, J., Viens, P., Birnbaum, D., Bertucci, F. (2008). Sixteen-Kinase Gene Expression Identifies Luminal Breast Cancers with Poor Prognosis. Cancer Res. 68: 767-776 [Abstract] [Full Text]  
• Sharma, S. V., Settleman, J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21: 3214-3231 [Abstract] [Full Text]  
• Hudis, C., Modi, S. (2007). Preoperative Chemotherapy for Breast Cancer: Miracle or Mirage?. JAMA 298: 2665-2667 [Full Text]  
• Naina, H. V.K., Harris, S., Matzdorff, A. C., Cathomas, R., Goldhirsch, A., von Moos, R., Aster, R. H., Bougie, D. W. (2007). Drug-Induced Immune Thrombocytopenia. NEJM 357: 1869-1871 [Full Text]  
• Winer, E. P., Harris, J. R., Smith, B. L., D'Alessandro, H. A., Brachtel, E. F. (2007). Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer. NEJM 357: 1640-1648 [Full Text]  
• Karamouzis, M. V., Konstantinopoulos, P. A., Papavassiliou, A. G., Mir, O., Berveiller, P., Pons, G., Hudis, C. A. (2007). Trastuzumab -- Mechanism of Action and Use. NEJM 357: 1664-1666 [Full Text]